FOI release

FOI requests received by the VMD between 1 January and 30 June 2015

Published 7 September 2015

Requests about our information and communications technology (ICT) arrangements

ATI reference number Subject
ATI 350 Request for information on certain contractual information the VMD may hold about our primary contracts relating to support services around help/service desk, desktop support and network support
ATI 347 Request for the document that holds future plan and strategy of the VMD’s ICT department, ICT Departmental Business Plan, ICT Technical Strategy, ICT Structure, ICT Capital budgets and programmes
ATI 345 Request for information relating to contact centre/call centre contracts or inbound network services contracts
ATI 344 Request for information relating to VMD’s Software licenses
ATI 343 Request for information relating to Fixed Telecommunications and Internet Services
ATI 342 Request for a list of suppliers providing outsourced ICT Services to the VMD at the current time - just those suppliers where annual spend (on any particular service) is in excess of £50,000 per annum
ATI 332 Request for information relating to ICT
ATI 330 Request for information relating to ICT contracts
ATI 329 Request for information relating to specific ICT contract(s) for Server Hardware Maintenance, Server Virtualisation License and Maintenance and Storage Area Network Maintenance/Support
ATI 327 Request for information relating to ICT

Requests for information about certain veterinary medicinal products

ATI reference number Subject
ATI 352/353/354 Three requests related to three products:

1. Amodip 1.25mg Chewable Tablets for Cats (UK/V/0525/001 or VM Number 20749/4044) – VMD ref: ATI352

2. Canergy 100mg Flavoured Tablets (UK/V/0542/001 or VM Number 4182/4019) – VMD ref: ATI353

3. Vivelin 1.25 mg Chewable Tablets for Cats (UK/V/0524/001 or VM Number 06043/4005) – VMD ref: ATI354

Requesting access to documents covering:

Part 1 – administrative information:
a) Scientific Advice given by any EU Member State
b) Summary of clinical efficacy.

Part 4 – efficacy:
a) study report of dose-confirmation study
b) study report of pivotal EU field trial.
ATI 339 Request for publicly available ecotoxicological data available in international literature in respect of a generic application for a Lincomycin-containing premix for medicated feeding stuff for the treatment of pigs and broilers
ATI 334 Request for information about efficacy at the various dosage levels relating to Calici Vaccine Research

Requests for information separately about what art we hold (none), our gas and electricity supply, whistleblowing in the VMD (none), and our use of external recruitment agencies

ATI reference number Subject
ATI 351 Request for information relating to any art owned by both the VMD and the Veterinary Products Committee Directorate
ATI 346 Request for information about contracts/agreements relating to the supply of gas and electricity
ATI 340 Request for information relating to unauthorised disclosures of official information and whistleblowing
ATI 333 Request for information relating to external recruitment agencies VMD used to hire for permanent or contract roles

Requests for information related to our pharmacovigilance work

ATI reference number Subject
ATI 341 Request for information relating to Pharmacovigilance data from the most recent PSUR for certain named products: Advocate Spot-on Solution, Frontline Comb, Frontline Spot on Cat 10% w/v Spot on Solution, Frontline Spot on Dog 10% w/v Spot on Solution, and Milbemax Tablets
ATI 338 Request for data regarding reported suspect adverse reaction incidence in cats after vaccination over the past 4/5 years
ATI 331 Request for reports of suspected adverse reactions to sheep dips from 1985 to 1992 and any information regarding the likely effects of the toxic chemicals during the same period

Requests for information related to our organophosphate work

ATI reference number Subject
ATI 336 Request for information relating to the report on results of blood samples taken from sheep dippers Sept/Nov 1991- is it still available and if the results for Sept-Dec 1992 were ever published?
ATI 335 Request for a report of results of blood samples taken between 22 September to 3 November 1991 and 1992 by the National Poisons Unit, in collaboration with the VMD and MAFF where the laboratory measured erythrocyte and plasma cholinesterase activities with an assay based on the method of Ellman et al
ATI 325 Request for all correspondence and request for meetings between DEFRA officials and the NFU since January 2009 on the subject of organophosphate poisoning

Requests from people or companies about whom we had received complaints, asking for the names of those that had complained – we treat each request on a case by case basis – in these cases we did not release the name of the complainant

ATI reference number Subject
ATI 355 Request for information relating to a complaint made by a company against another for the way it had advertised a veterinary medicinal product that was available on veterinary prescription only
ATI 348 Request for information relating to a complaint made by a company against another for the way it had placed a veterinary medicine on the market or made medicinal claims without a marketing authorisation under the VMRs
ATI 326 Request for information relating to a complaint made by a company against another for the way it had placed a veterinary medicine on the market

Requests for information about residues in horses, Crufts and certain veterinary sales data

ATI reference number Subject
ATI 349 Request for the veterinary sales data, in kg of active ingredient, for all cephalosporins; and the data for 3rd and 4th generation cephalosporins in kg of active ingredient (i.e. was it 1,200 kg exactly)
ATI 337 Request for all communications involving the chairman sent and received between (and including) March 6 and 18 March 2015, relating in any way to the death of a dog (Thendara Satisfaction, known as Jagger) which had competed at Crufts
ATI 328 Request for information relating to horses submitted for slaughter for human consumption in (i) 2013 and (ii) 2014 sampled by the VMD